YuvaBio strikes obesity drug discovery deal with Northstrive

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Companies harness AI to identify drugs that target mitochondrial dysfunction and address the underlying causes of metabolic conditions.

Longevity biotech Yuva Biosciences has inked a development and license agreement with Northstrive Biosciences aimed at advancing pharmaceutical therapies for obesity, type 2 diabetes and other cardiometabolic diseases by targeting mitochondrial dysfunction. The agreement provides YuvaBio with upfront and milestone payments as well as royalties on future sales of therapeutic products developed using the identified compounds.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE